# NSRX (Nasus Pharma Ltd) - SEC EDGAR Financial Statements

> Nasus Pharma Ltd reported $1.24B in revenue and a net loss of $5.86M for the fiscal year ended December 31, 2025, with a -0.4% operating margin.

- Canonical: https://convexityos.com/fundamentals/NSRX
- Markdown: https://convexityos.com/fundamentals/NSRX.md
- SEC CIK: 0002029039
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 21, 2026, 05:02 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002029039&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $1.24B | Dec 31, 2025 |
| Operating Income | FY 2025 | -$4.90M | -0.4% margin |
| Net Income | FY 2025 | -$5.86M | -0.5% net margin |
| Diluted EPS | FY 2025 | -$0.72 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$4.93M | -0.4% FCF margin |
| Cash & ST Investments | Dec 31, 2025 | $1.24M | Total debt: $118K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | $1.24B | -- | -- |
| Research & Development | $2.24M | $335K | $567K |
| Total Operating Expenses | $4.90M | $1.08M | $1.15M |
| **Operating Income** | -$4.90M | -$1.08M | -$1.15M |
| Interest Expense | -$78K | $29K | $49K |
| **Net Income** | -$5.86M | -$1.53M | -$1.05M |
| Basic EPS | -$0.72 | -$0.22 | -$0.15 |
| **Diluted EPS** | -$0.72 | -$0.22 | -$0.20 |
| Basic Shares Outstanding | 8.0M | 7.0M | 6.9M |
| Diluted Shares Outstanding | 8.0M | 7.0M | 7.1M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $1.24M | $284K |
| **Cash & Short-Term Investments** | $1.24M | $284K |
| Other Current Assets | $186K | $29K |
| **Total Current Assets** | $4.86M | $457K |
| Property, Plant & Equipment, Net | $14K | -- |
| **Total Non-Current Assets** | $149K | $260K |
| **Total Assets** | $5.00M | $717K |
| Accounts Payable | $829K | $651K |
| **Total Current Liabilities** | $2.16M | $3.93M |
| **Total Non-Current Liabilities** | $73K | $0 |
| **Total Liabilities** | $2.24M | $3.93M |
| **Total Debt (incl. Leases)** | $118K | -- |
| Common Stock | -- | $20K |
| Retained Earnings | -$18.52M | -$12.66M |
| **Total Stockholders' Equity** | $2.77M | -$3.21M |
| Total Equity | $2.77M | -$3.21M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $1.24M | $284K |
| **Cash & Short-Term Investments** | $1.24M | $284K |
| Other Current Assets | $186K | $29K |
| **Total Current Assets** | $4.86M | $457K |
| Property, Plant & Equipment, Net | $14K | -- |
| **Total Non-Current Assets** | $149K | $260K |
| **Total Assets** | $5.00M | $717K |
| Accounts Payable | $829K | $651K |
| **Total Current Liabilities** | $2.16M | $3.93M |
| **Total Non-Current Liabilities** | $73K | $0 |
| **Total Liabilities** | $2.24M | $3.93M |
| **Total Debt (incl. Leases)** | $118K | -- |
| Common Stock | -- | $20K |
| Retained Earnings | -$18.52M | -$12.66M |
| **Total Stockholders' Equity** | $2.77M | -$3.21M |
| Total Equity | $2.77M | -$3.21M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$5.86M | -$1.53M | -$1.05M |
| Stock-Based Compensation | $447K | $10K | $39K |
| Change in Payables | $152K | -$5.0K | -$116K |
| **Operating Cash Flow** | -$4.92M | -$665K | -$1.03M |
| Capital Expenditure | -$14K | -- | -- |
| **Free Cash Flow** | -$4.93M | -- | -- |
| **Investing Cash Flow** | -$3.01M | -- | -- |
| Common Stock Issued | $8.48M | -- | -- |
| **Financing Cash Flow** | $8.92M | $770K | $1.05M |
| **Net Change in Cash** | $980K | $101K | $39K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Operating Margin** | -0.4% | -- | -- |
| **Net Profit Margin** | -0.5% | -- | -- |
| Return on Equity (ROE) | -211.6% | -- | -- |
| Return on Assets (ROA) | -117.0% | -213.7% | -- |
| Current Ratio | 2.24x | 0.12x | -- |
| Quick Ratio | 0.57x | 0.07x | -- |
| Debt to Equity | 0.04x | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
